SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

The upcoming Phase 3 REGAL trial readout for SELLASs AML treatment GPS dominates discussion, with traders focused on the binary clinical catalyst. Bulls anticipate strong results, while skeptics cite the stocks sharp volatility and warn of failure risk or a sell-the-news reaction; claims of short-term manipulation remain speculation.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summits FDA review of ivonescimab for EGFR-mutated lung cancer is driving a binary-outcome debate over approval versus a possible rejection or request for more evidence. Bulls point to strong progression-free-survival results and encouraging survival trends, while bears focus on the FDAs stated need for statistically significant overall-survival evidence; recent weakness has also prompted speculation about a negative outcome, though traders say price action alone is not proof.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQs sharp after-hours drop drew attention as traders linked the move to the FAAs nationwide ground stop after communications problems, while speculation about a cyberattack or AI involvement remained unverified. The discussion also reflected wider pressure on tech and AI stocks tied to uncertainty around Nvidia, with traders divided between seeing the selloff as an overreaction and expecting further weakness.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivians volatile, weak share performance is driving debate, with traders blaming heavy short-selling and persistent selling pressure while bulls point to improving deliveries, the R2 ramp, and upcoming autonomy developments. Sentiment remains split between concern over cash burn and execution and hopes that the companys growth initiatives can improve its outlook.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Reported takeover discussions involving Silver Lake and Saudi Arabias PIF are driving speculation, though no deal is confirmed; traders disagree over whether a potential offer would undervalue Unity. The interest is reinforced by strong quarterly results and the companys first GAAP-profitable quarter, with bullish call activity and breakout chatter alongside skepticism about the rally.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius selloff is being tied to its earnings outlook and delays in activating third-party data-center capacity, which push expected revenue into a later period and have prompted analyst price-target cuts. Traders are divided between viewing the execution and heavy-capex concerns as a reason for further downside and treating the drop as an overreaction, with broader weakness in AI and neocloud stocks adding pressure.

American Airlines Group, Inc. is a holding company, which engages in the operation of a network carrier through its principal wholly owned mainline operating subsidiary, American. The firm offers air transportation for passengers and cargo. It operates through the following geographical segments: Domestic, Latin America, Atlantic, and Pacific. The company was founded on December 9, 2013, and is headquartered in Fort Worth, TX.

American Airlines Group Inc

Reports of an FAA nationwide ground stop tied to air-traffic-control communications problems are drawing attention to AAL, with traders discussing possible departure delays and rerouting. Some characterize the disruption as brief, while speculation about its cause remains unverified.

HawKeye 360, Inc. engages in the provision of defense technology. It offers spectrum monitoring, maritime intelligence, air defence radar monitoring, GNSS interference detection, and communications mapping. Its costumers include a wide range of commercial, government and international entities. The company was founded by Charles T. Clancy, Robert G. McGwier, Chris DeMay and John Serafini in 2015 and is headquartered in Herndon, VA.

HawkEye 360 Inc.

HAWK is drawing attention after reporting record third-quarter revenue and raising its full-year outlook, with traders also highlighting international growth, contract demand, and plans for lower-cost satellites. The community reaction is broadly bullish on the results and rally, though claims of institutional accumulation and further upside remain speculative.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs abrupt departure is driving debate over Nvidias leadership transition, with traders speculating about his return and possible successors while others worry about leadership uncertainty and scrutiny of chip exports to China. Bulls argue Nvidias business remains strong and point to earnings, while bears see unresolved risks weighing on confidence.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novos stronger-than-expected quarterly results and raised full-year outlook, driven largely by demand for its Wegovy pill, have fueled renewed buying interest. Traders are debating whether the oral drugs momentum can support a sustained recovery amid Lilly competition and concerns about Novos execution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pictet Asset Management Holding SA Trims Stake in Amicus Therapeutics, Inc. $FOLD

Pictet Asset Management Holding SA lessened its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 70.6% during the fourth quarter, according to the company in its most...

Universal Beteiligungs und Servicegesellschaft mbH Decreases Holdings in Amicus Therapeutics, Inc. $FOLD

Universal Beteiligungs und Servicegesellschaft mbH cut its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 28.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 231,337 shares of the bi...

Best Biotech Stocks To Add to Your Watchlist - April 28th

Danaher, Medpace, Vertex Pharmaceuticals, Oruka Therapeutics, Amicus Therapeutics, argenex, and Moderna are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...

CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)

Key PointsIncreased Amicus Therapeutics stake by 1,476,861 shares; estimated trade size $21.17 million (based on average price from January to March 2026...

Amicus Therapeutics (NASDAQ:FOLD) Sets New 12-Month High  - Time to Buy?

Amicus Therapeutics (NASDAQ:FOLD) Sets New 1-Year High - Should You Buy...

Massachusetts Financial Services Co. MA Has $1.79 Million Position in Amicus Therapeutics, Inc. $FOLD

Massachusetts Financial Services Co. MA reduced its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 96.6% during the 4th quarter, according to the company in its most recent...

Amicus Therapeutics (NASDAQ:FOLD) Share Price Crosses Above 200 Day Moving Average - Here's What Happened

Amicus Therapeutics (NASDAQ:FOLD) Shares Pass Above 200 Day Moving Average - What's Next...

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Rating of "Hold" by Brokerages

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) have received an average recommendation of "Hold" from the thirteen analysts that are currently covering the stock, MarketBeat...

Amicus Therapeutics (NASDAQ:FOLD) Hits New 1-Year High - Time to Buy?

Amicus Therapeutics (NASDAQ:FOLD) Hits New 1-Year High - Still a Buy...

Capricorn Fund Managers Ltd Invests $3 Million in Amicus Therapeutics, Inc. $FOLD

Capricorn Fund Managers Ltd bought a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the...

Amicus Therapeutics, Inc. is a biotechnology company, which engages in discovering, developing, and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

Amicus Therapeutics Inc

Amicus Stock Surges To Near 2-Year Highs On BioMarin's $4.8B Buyout Deal

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>The deal values Amicus at $14.50 per share, representing a 33% premium to its $10.90 closing price on Thursday.</li><li>Amicus settled its patent dispute with Indian drugmakers Aurobindo Pharma and Lupin over proposed generic versions of Galafold.</li><li>BioMarin plans to fund the acquisition with a mix of existing cash and about $3.7 billion in new debt</li></ul>Amicus Therapeutics (FOLD) shares jumped more than 30% in on Friday, to their highest level since January 2024, after BioMarin Pharmaceutical (BMRN) agreed to acquire the company in a $4.8 billion all-cash deal.The deal values Amicus at $14.50 per share, representing a 33% premium to its $10.90 closing price on Thursday. The transaction is expected to close in the second quarter of fiscal 2026. Biomarin shares gained 6.6%.Both <a href="https://stocktwits.com/symbol/FOLD">FOLD</a> and <a href="https://stocktwits.com/symbol/BMRN">BMRN</a> were among the top trending tickers on Stocktwits.<h2 class="st-heading-2">Portfolio Expansion And Revenue Pipeline</h2>The acquisition will expand BioMarin’s portfolio, adding two new treatments to its existing medicines for rare inherited metabolic disorders.Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease generated $599 million in combined net revenues over the past four quarters. U.S. exclusivity for Galafold is projected through January 2037 following recent patent settlements.The deal is expected to boost revenue as soon as it closes and add to earnings within the first year. BioMarin expects the acquisition to become meaningfully more accretive from 2027.The company plans to fund the acquisition with a mix of existing cash and about $3.7 billion in new debt, with Morgan Stanley providing a bridge financing commitment.<h2 class="st-heading-2">IP Dispute Update</h2>Separately, Amicus settled its patent dispute with Indian drugmakers Aurobindo Pharma and Lupin over proposed generic versions of Galafold. Under the agreements, the companies will be allowed to launch generics in the U.S. starting January 30, 2037, subject to FDA approval.As part of the settlement, all ongoing Hatch-Waxman litigation between the parties will be terminated, and U.S. antitrust authorities will review the agreements.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for Biomarin on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘high' message volumes.&nbsp;<figure class="image"><img style="aspect-ratio:904/100;" src="https://news.stocktwits-cdn.com/BMRN_png_a8236939f5.webp" alt="BMRN.png" width="904" height="100"><figcaption>BMRN's Sentiment Meter And Message Volumes at Premarket on Dec. 18, 2025 | Source: Stocktwits</figcaption></figure>One user highlighted the visibility of BMRN’s FY2027 revenue target.<stembedurl>https://stocktwits.com/DairyQueen505/message/639674012</stembedurl>Retail sentiment for Amicus on the platform remained in the ‘extremely bullish’ zone over the past 24 hours, amid ‘extremely high message volumes.<figure class="image"><img style="aspect-ratio:922/99;" src="https://news.stocktwits-cdn.com/fold_png_a408903f4b.webp" alt="fold.png" width="922" height="99"><figcaption>FOLD's Sentiment Meter and Message Volumes at Premarket on Dec. 18, 2025 | Source: Stocktwits</figcaption></figure>Year-to-date, FOLD stock has gained 15% while BMRN has declined over 20%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/this-new-product-launch-is-lifting-amesite-shares-premarket/cLeiw0iREs7">This New Product Launch Is Lifting Amesite Shares Premarket — Here’s What Investors Are Watching</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

The acquisition will add two new treatments to BioMarin’s existing medicines for rare inherited metabolic disorders.

Biomarin Pharmaceutical Inc. - Registered Shares

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

FOLD News